
CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors
November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung
Updated on: October 17,2023
129

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors
November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung
Updated on:October 17,2023
129
